TY - JOUR
T1 - Circulating Biomarkers for the Early Diagnosis and Management of Hepatocellular Carcinoma with Potential Application in Resource-Limited Settings
AU - Pan, Annabelle
AU - Truong, Thai N.
AU - Su, Ying Hsiu
AU - Dao, Doan Y.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/2
Y1 - 2023/2
N2 - Hepatocellular carcinoma (HCC) is among the world’s third most lethal cancers. In resource-limited settings (RLS), up to 70% of HCCs are diagnosed with limited curative treatments at an advanced symptomatic stage. Even when HCC is detected early and resection surgery is offered, the post-operative recurrence rate after resection exceeds 70% in five years, of which about 50% occur within two years of surgery. There are no specific biomarkers addressing the surveillance of HCC recurrence due to the limited sensitivity of the available methods. The primary goal in the early diagnosis and management of HCC is to cure disease and improve survival, respectively. Circulating biomarkers can be used as screening, diagnostic, prognostic, and predictive biomarkers to achieve the primary goal of HCC. In this review, we highlighted key circulating blood- or urine-based HCC biomarkers and considered their potential applications in resource-limited settings, where the unmet medical needs of HCC are disproportionately highly significant.
AB - Hepatocellular carcinoma (HCC) is among the world’s third most lethal cancers. In resource-limited settings (RLS), up to 70% of HCCs are diagnosed with limited curative treatments at an advanced symptomatic stage. Even when HCC is detected early and resection surgery is offered, the post-operative recurrence rate after resection exceeds 70% in five years, of which about 50% occur within two years of surgery. There are no specific biomarkers addressing the surveillance of HCC recurrence due to the limited sensitivity of the available methods. The primary goal in the early diagnosis and management of HCC is to cure disease and improve survival, respectively. Circulating biomarkers can be used as screening, diagnostic, prognostic, and predictive biomarkers to achieve the primary goal of HCC. In this review, we highlighted key circulating blood- or urine-based HCC biomarkers and considered their potential applications in resource-limited settings, where the unmet medical needs of HCC are disproportionately highly significant.
KW - circulating biomarkers
KW - early detection
KW - hepatocellular carcinoma
KW - liver cancer
KW - low-to-middle-income countries (LMICs)
KW - resource-limited settings
UR - http://www.scopus.com/inward/record.url?scp=85149130742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149130742&partnerID=8YFLogxK
U2 - 10.3390/diagnostics13040676
DO - 10.3390/diagnostics13040676
M3 - Review article
C2 - 36832164
AN - SCOPUS:85149130742
SN - 2075-4418
VL - 13
JO - Diagnostics
JF - Diagnostics
IS - 4
M1 - 676
ER -